Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test

By Brian Orelli, PhD – May 21, 2020 at 2:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The test could diagnose individuals in 20 minutes without the need for lab equipment.

GlaxoSmithKline (GSK -0.56%) is working with Mammoth Biosciences to develop a CRISPR-based test for SARS-CoV-2, the coronavirus that causes COVID-19.

CRISPR is a gene-editing tool that's typically being used by companies and researchers aiming to develop cures for diseases. The system can edit DNA in a specific place by searching the DNA for a specific sequence, then cutting the DNA at that spot to make the edit.

Mammoth, on the other hand, is using CRISPR's ability to search for a specific DNA sequence to detect the presence of genes from the virus, then using the cutting as a reporter of a positive test.

Unlike most current COVID-19 tests, the CRISPR-based test would be handheld and wouldn't require laboratory-based machines to process the samples. The disposable tests could give results in less than 20 minutes.

Mammoth and GlaxoSmithKline hope to have the test submitted to the Food and Drug Administration for emergency use authorization by the end of 2020. The test will first be marketed for use by healthcare providers who would have employees perform them at testing sites, but the companies eventually plan to make it available for use by consumers at home.

Man in a car getting a nasal swab test

Image source: Getty Images.

The companies didn't disclose the financial terms of their agreement nor how much the test is expected to cost. After developing a COVID-19 test, the companies plan to explore using Mammoth's technology to develop other diagnostic tests for consumer use.

Mammoth and GlaxoSmithKline are trailing Sherlock Biosciences, which gained FDA authorization for its CRISPR-based COVID-19 test earlier this month, although Sherlock's current version still requires a machine in a laboratory to process the test. Sherlock is also working on a self-contained test that could be used by individuals at home.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
$28.66 (-0.56%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.